

1 **Febrile Seizure Risk Following Monovalent COVID-19 mRNA Vaccination in US Children**  
2 **Aged 2-5 Years**

3  
4 Steven A Anderson, PhD, MPP,<sup>1</sup> Elizabeth R Smith, BS,<sup>2</sup> Zhiruo Wan, MS<sup>2</sup>, Kandace L Amend,  
5 PhD, MPH,<sup>3</sup> Alex Secora, PhD<sup>4</sup>, Djeneba Audrey Djibo, PhD, MSBME,<sup>5</sup> Kamran Kazemi, BS,<sup>2</sup>  
6 Jennifer Song, MA, MURP<sup>3</sup>, Lauren E Parlett, PhD<sup>6</sup>, John D Seeger, DrPH, PharmD<sup>3</sup>, Nandini  
7 Selvam, PhD, MPH<sup>4</sup>, Cheryl N McMahill-Walraven, PhD, MSW,<sup>5</sup> Mao Hu, BS,<sup>2</sup> Yoganand  
8 Chillarige, MPA<sup>2</sup>, Richard A Forshee, PhD<sup>1</sup>

9  
10 **Affiliations:** <sup>1</sup> US Food and Drug Administration, Silver Spring, MD, USA; <sup>2</sup> Acumen LLC,  
11 Burlingame, CA, USA; <sup>3</sup> Optum Epidemiology, Boston, MA, USA; <sup>4</sup> IQVIA, Falls Church, VA,  
12 USA; <sup>5</sup> CVS Health, Blue Bell, PA, USA; <sup>6</sup> Cernelon Research, Inc., Wilmington, DE, USA

13  
14  
15 **Address correspondence to:** Richard A. Forshee, PhD, Deputy Director, Office of Biostatistics  
16 and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food & Drug  
17 Administration, 10903 New Hampshire Ave., Silver Spring, MD, 20993,  
18 [richard.forshee@fda.hhs.gov](mailto:richard.forshee@fda.hhs.gov), (240) 402-8631

19  
20 **Short title:** Febrile Seizure Following COVID-19 mRNA Vaccination

21  
22 **Conflict of Interest Disclosures:** Both Drs Djibo and McMahill-Walraven are CVS Health  
23 employees.

24 **Data Sharing Statement:** The study protocol was posted previously. Data analyses and related  
25 documents can be made available where needed, by contacting the corresponding author. De-  
26 identified participant data will not be shared without approval from the data partners.

27  
28 **Funding/Support:** The US Food and Drug Administration provided funding for this study and  
29 contributed as follows: led the design of the study, interpretation of the results, writing of the  
30 manuscript, decision to submit, and made contributions to the coordination of data collection and  
31 analysis of the data.

32  
33 **Abbreviations:**

34 BEST – Biologics Effectiveness and Safety  
35 CBER – Center for Biologics Evaluation and Research  
36 CI – Confidence Interval  
37 CPT – Current Procedural Terminology  
38 CVX – IIS code indicating vaccination  
39 DTaP – Diphtheria, Tetanus, Pertussis  
40 EUA – Emergency Use Authorization  
41 FDA – Food and Drug Administration  
42 HCPCS – Healthcare Common Procedure Coding System  
43 ICD-10-CM – International Classification of Diseases, Tenth Revision, Clinical Modification  
44 IIS – Immunization Information System

45 IRR – Incidence Rate Ratio  
46 MMR/MMRV – Measles, Mumps, Rubella/Measles, Mumps, Rubella, Varicella  
47 mRNA – Messenger ribonucleic acid  
48 NDC – National Drug Codes  
49 NRS – Near Real-Time Surveillance  
50 PCV13 – Pneumococcal Conjugate Vaccine  
51 PPV – Positive Predictive Value  
52 RD – Risk Difference  
53 SAE – Systemic Adverse Event  
54 SCCS – Self-Controlled Case Series  
55 U.S. – United States  
56 VAERS – Vaccine Adverse Event Reporting System  
57  
58

### 59 **Article Summary**

60 In this self-controlled case series study, researchers evaluated whether there is an elevated risk of  
61 febrile seizure immediately following monovalent COVID-19 mRNA vaccination.  
62  
63

### 64 **What’s Known on This Subject**

65 The United States Food and Drug Administration previously noted a potential safety concern for  
66 seizure in children aged 2-5 years receiving the ancestral monovalent COVID-19 mRNA  
67 vaccines.  
68

### 69 **What This Study Adds**

70 In this self-controlled case series that included participants aged 2-5 years from three commercial  
71 insurance databases, the incidence rate ratio of febrile seizures was significantly elevated in the  
72 0-1 days following mRNA-1273 administration. Absolute risk was small.  
73

74 **Contributors Statement**

75 Steven A Anderson and Richard A Forshee conceptualized and designed the study, interpreted  
76 data and analysis, drafted the manuscript, critically reviewed and revised the manuscript, and  
77 provided supervision of the analysis.

78 Elizabeth R Smith conceptualized and designed the study, interpreted data and analysis, drafted  
79 the manuscript, and critically reviewed and revised the manuscript.

80 Zhiruo Wan, Kamran Kazemi, and Mao Hu conceptualized and designed the study, designed  
81 data collection instruments, carried out the data analysis, and critically reviewed and revised the  
82 manuscript.

83 Yoganand Chillarige conceptualized and designed the study, critically reviewed and revised the  
84 manuscript, and provided supervision of the analysis.

85 Kandace L Amend, Alex Secora, Djeneba Audrey Djibo, Jennifer Song, Lauren E Bartlett, John  
86 D Seeger, Nandini Selvam, and Cheryl N McMahill-Walraven carried out data analysis and  
87 critically reviewed and revised the manuscript.

88 All authors approved the final manuscript as submitted and agree to be accountable for all  
89 aspects of the work.

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109 **ABSTRACT (Word Count: 244)**

110 **Objective**

111 To evaluate febrile seizure risk following monovalent COVID-19 mRNA vaccination among  
112 children aged 2-5 years.

113 **Methods**

114 The primary analysis evaluated children who had a febrile seizure outcome in the 0-1 days  
115 following COVID-19 vaccination. A self-controlled case series analysis was performed in three  
116 commercial insurance databases to compare the risk of seizure in the risk interval (0-1 days) to a  
117 control interval (8-63 days).

118 The exposure of interest was receipt of dose 1 and/or dose 2 of monovalent COVID-19 mRNA  
119 vaccinations.

120 The primary outcome was febrile seizure (0-1 day risk interval).

121 A conditional Poisson regression model was used to compare outcome rates in risk and control  
122 intervals and estimate incidence rate ratios (IRR) and 95% confidence intervals (CIs). Meta-  
123 analyses were used to pool results across databases.

124 **Results**

125 The primary meta-analysis found a statistically significant increased incidence of febrile seizure,  
126 in the 0-1 days following mRNA-1273 vaccination compared to the control interval (IRR: 2.52,  
127 95% CI: 1.35 to 4.69, risk difference (RD)/100,000 doses = 3.22 (95%CI -0.31 to 6.75)). For the  
128 BNT162b2 vaccination, the IRR was elevated but not statistically significant (IRR: 1.41, 95%CI:  
129 0.48 to 4.11, RD/100,000 doses = -0.25 (95%CI -2.75 to 2.24)).

130 **Conclusions**

131 Among children aged 2-5 years, the analysis showed a small elevated incidence rate ratio of  
132 febrile seizures in the 0-1 days following the mRNA-1273 vaccination. Based on the current  
133 body of scientific evidence, the safety profile of the monovalent mRNA vaccines remains  
134 favorable for use in young children.

135

136

137 **INTRODUCTION (Word Count: 586)**

138 On June 17, 2022 the United States (U.S.) Food and Drug Administration (FDA) granted  
139 emergency use authorization (EUA) for the monovalent COVID-19 mRNA vaccines developed  
140 by Pfizer-BioNTech (BNT162b2) for use in individuals aged 6 months through 4 years, and  
141 Moderna (mRNA-1273) for use in individuals aged 6 months through 17 years.<sup>1</sup> The BNT162b2  
142 vaccine was authorized as a three-dose primary series, and the mRNA-1273 vaccine was  
143 authorized as a two-dose primary series in young children. As of April 18, 2023 these initial  
144 formulations of the mRNA vaccines are no longer available for use and have been replaced by  
145 updated formulations based on currently circulating variants.<sup>2</sup>

146 Fever was one of the commonly observed systemic adverse events (SAEs) in children in the  
147 clinical trials of both mRNA vaccines, and in some instances, may result in febrile seizures. In  
148 clinical trials of mRNA-1273 vaccinations among individuals aged 24-36 months,<sup>3</sup> fever  
149 ( $\geq 38.0^{\circ}\text{C}$ ) was observed in 11.3% and 18.9% of participants following dose 1 and 2,  
150 respectively. Grade 3 fever ( $39.6^{\circ}\text{C}$ - $40.0^{\circ}\text{C}$ ) was observed in 0.3% and 1.2% of participants  
151 following dose 1 and 2, respectively, and grade 4 fever ( $>40.0^{\circ}\text{C}$ ) was observed in 0.3% and  
152 0.3% of participants following dose 1 and 2. Fever was the most common grade 3/4 SAE  
153 observed in individuals aged 37 months – 5 years. Fever ( $\geq 38.0^{\circ}\text{C}$ ) was observed in 7.7% and  
154 16.0% of participants aged 37 months – 5 years following dose 1 and 2, respectively. Grade 3  
155 fever ( $39.0^{\circ}\text{C}$ - $40.0^{\circ}\text{C}$ ) was observed in 1.1% and 2.9% of participants following dose 1 and 2,  
156 and grade 4 fever ( $>40.0^{\circ}\text{C}$ ) was observed in 0% and 0.2% of participants following dose 1 and  
157 2.

158 For BNT162b2, the most common severe systemic reaction among individuals aged 2-4 years  
159 was fever.<sup>4</sup> Fever ( $\geq 38.0^{\circ}\text{C}$ ) was observed in 5.2%, 4.9% and 5.1% of participants following

160 dose 1, 2, and 3 respectively. Fever ( $>38.9^{\circ}\text{C}$  to  $40.0^{\circ}\text{C}$ ) was observed in 0.7%, 1.1%, and 0.7%  
161 of participants following dose 1, 2, and 3 respectively, and fever ( $>40.0^{\circ}\text{C}$ ) was observed in  
162 0.1%, 0.1%, and 0% of participants following dose 1, 2, and 3.

163 In a prior safety monitoring study, the FDA Center for Biologics Evaluation and Research  
164 (CBER) conducted near real-time surveillance (NRS) of the authorized COVID-19 vaccines in  
165 the pediatric population.<sup>5,6</sup> NRS allows for the rapid identification of statistical signals for  
166 potentially elevated risk of evaluated outcomes following vaccination. Of the 19 outcomes  
167 evaluated for increased risk following exposure to the monovalent COVID-19 vaccines, the NRS  
168 detected a statistical signal for seizures/convulsions across the different doses (dose 1 and/or  
169 dose 2) following exposure to BNT162b2 in individuals aged 2-4 years and mRNA-1273 in  
170 individuals aged 2-5 years. Further evaluation of the potential signal was necessary as NRS was  
171 designed to be sensitive but not specific for screening and detection purposes.

172 The NRS used a broad outcome definition for seizures/convulsions and evaluated a 0-7 day risk  
173 interval. However, further examination of the data used in the NRS study indicated that most of  
174 the identified seizures/convulsions cases were febrile seizures. Accordingly, this current study  
175 uses the febrile case definition for children under the age of 5 years and a risk interval of 0-1  
176 days, as used in prior FDA studies, to ensure that febrile cases are more likely to be associated  
177 with vaccination rather than other causes.<sup>7</sup> This manuscript summarizes results of a self-  
178 controlled case series (SCCS) study conducted in 3 commercial insurance databases in the  
179 pediatric population aged 2-5 years. The primary objective was to determine the risk of febrile  
180 seizure in the 0-1 days following vaccination.

181 **METHODS (Word Count: 755)**

## 182 **Data Sources**

183 This study used commercial health claims data from the Carelon Research, CVS Health, and  
184 Optum databases to capture COVID-19 vaccination data and medical claims data relevant to the  
185 outcomes of interest. COVID-19 vaccination data from participating Immunization Information  
186 System (IIS) jurisdictions were used to supplement claims data to improve capture of COVID-19  
187 vaccinations (eTable 1).<sup>8</sup>

## 188 **Study Population, Study Period, and Study Design**

189 The study population consisted of enrollees aged 2-4 years who received a BNT162b2 COVID-  
190 19 vaccination and enrollees aged 2-5 years who received a mRNA-1273 COVID-19  
191 vaccination. To be included in the study population, individuals were required to be continuously  
192 enrolled in the health plan at least 42 days prior to receiving the vaccine dose of interest.  
193 Individuals were excluded if they had COVID-19 vaccination patterns that did not conform to  
194 expectations for the analysis of interest, such as subsequent doses occurring fewer than 3 days  
195 apart or receipt of more doses than approved. The start of the study period was June 17, 2022,  
196 the EUA for COVID-19 vaccinations in these age groups. The study end date was database  
197 specific (eTable 1).

198 We used a SCCS study design to compare the incidence of seizure outcomes following  
199 monovalent COVID-19 pediatric vaccine administration within pre-specified risk intervals  
200 (primary outcome: febrile seizures, 0-1 days; secondary outcomes: febrile seizures, 0-7 days and  
201 seizures/convulsions, 0-7 days) to a control interval (day 8 through the end of the 63 day  
202 observation period). In the primary outcome analysis, we included a washout period (days 2-7)  
203 prior to the control interval; for secondary outcomes, this period was included in the risk interval.

## 204 **Exposures and Outcomes**

205 The primary exposure of interest was the receipt of dose 1 and/or dose 2 of the monovalent  
206 COVID-19 BNT162b2 (individuals aged 2-4 years) or mRNA-1273 (individuals aged 2-5 years)  
207 pediatric vaccines. Vaccinations were identified in administrative claims data through vaccine-  
208 specific codes including Current Procedural Terminology (CPT)/Healthcare Common Procedure  
209 Coding System (HCPCS) codes and National Drug Codes (NDCs) in the professional, outpatient,  
210 inpatient, or pharmacy care settings, as well as CVX (vaccine administered codes) in IIS data  
211 (eTable 2).

212 The primary outcome of interest was febrile seizures (0-1 day risk window). Secondary  
213 outcomes included febrile seizures (0-7 day risk window) and seizures/convulsions (0-7 day risk  
214 window). Seizure outcomes were identified with International Classification of Diseases, Tenth  
215 Revision, Clinical Modification (ICD-10-CM) codes in any diagnosis position in the inpatient  
216 and emergency department settings. Febrile seizures were identified using ICD-10-CM codes  
217 R56.00 and R56.01; seizures/convulsions were identified using ICD-10-CM codes R56.00,  
218 R56.01, and R56.9. Incident seizure outcomes were defined as the first recorded seizure event for  
219 an individual during the observation period following the exposure, with no previously identified  
220 outcomes in the 42-day clean interval prior to outcome.

## 221 **Statistical Analysis**

222 We characterized all eligible vaccinees as well the subset of vaccinees with outcomes, including  
223 stratification by age, sex, U.S. region, and concomitant vaccination status. We used a conditional  
224 Poisson regression model to compare the febrile seizure rates in risk and control intervals and  
225 estimate the incidence rate ratio (IRR). From the conditional Poisson regression model, we



226 derived the risk difference (RD) per 100,000 vaccinations and per 100,000 person-years.<sup>9</sup> We  
227 performed meta-analyses to pool results from all three databases, allowing for higher precision  
228 and statistical power. Meta-analyses were prespecified as primary and individual database results  
229 were specified as secondary. We conducted random-effects meta-analysis to account for  
230 between-study heterogeneity across multiple data sources and fixed-effect meta-analysis to  
231 address concerns that the random-effects method may not perform well when the number of  
232 studies is small. Random-effects meta-analyses are reported in text. We used Cochran's Q  
233 statistic and Higgins & Thompson's  $I^2$  statistic to assess between-study heterogeneity.<sup>10</sup>

234 We conducted a sensitivity analysis restricting to enrollees without concomitant MMR/MMRV  
235 (Measles, Mumps, Rubella/Measles, Mumps, Rubella, Varicella), DTaP (Diphtheria, Tetanus,  
236 Pertussis), PCV13 (Pneumococcal Conjugate Vaccine), or influenza vaccination on the same day  
237 as COVID-19 vaccination. We also adjusted for potential time-varying confounding due to the  
238 length of the observation period by adjusting for baseline febrile seizure risk estimated from  
239 within-study background rates. We conducted a sensitivity analysis implementing the Farrington  
240 adjustment for event-dependent exposure.<sup>11</sup> Finally, we conducted a sensitivity analysis adjusting  
241 for the PPV of our primary outcome using the Schenker and Rubin method and the PPV derived  
242 by the Sentinel initiative (PPV 91%; 95% CI 85-95%).<sup>11,12</sup> Medical record review of the cases  
243 identified in the present study is ongoing.

244 All analyses were conducted using R (version 4.1.2, R Foundation for Statistical Computing) and  
245 SAS v. 9.4 (SAS Institute Inc., Cary, NC, United States).

## 246 **RESULTS (Word Count: 638)**

### 247 **Primary Outcome**

## 248 **Descriptive Analyses**

249 There were 288,754 BNT162b2 and 192,540 mRNA-1273 vaccinations observed among  
250 163,733 and 110,126 enrollees, respectively. In the primary analysis, 88 cases of febrile seizures  
251 were observed following vaccination with BNT162b2, of which 7 cases were observed during  
252 the risk interval (days 0-1) and 81 were observed during the control interval (days 8-63) (Table  
253 1). There were 67 cases of febrile seizures observed following vaccination with mRNA-1273, of  
254 which 10 cases were observed during the risk interval (days 0-1) and 57 during the control  
255 interval (days 8-63).

256 Table 1 provides a summary of the baseline characteristics of the eligible vaccinated population  
257 as well as the population who experienced an outcome in the primary analysis. Among all  
258 eligible vaccinees, sex was evenly distributed and age was generally evenly distributed.  
259 However, the population experiencing outcomes skewed younger than the ‘all eligible vaccinees’  
260 population, with a greater proportion of cases observed in those aged 2 years compared to all  
261 other age groups.

## 262 **Inferential Analyses**

263 Meta-analyzed IRRs for primary and sensitivity analyses are presented in Figure 1 and Table 2.  
264 The primary meta-analysis found more than twice the incidence of the primary outcome febrile  
265 seizure 0-1 days following the mRNA-1273 vaccine compared to control interval (IRR: 2.52,  
266 95% CI: 1.35 to 4.69) with low between-database heterogeneity ( $I^2=0%$ , 95% uncertainty  
267 interval 0-78%; Cochran’s Q test p-value = 0.62). For the BNT162b2 vaccination, the IRR was  
268 elevated but not statistically significant (IRR: 1.41, 95%CI: 0.48 to 4.11) with moderate  
269 between-database heterogeneity ( $I^2=51%$ , 95% uncertainty interval 0-86%; Cochran’s Q test p-

270 value = 0.13). We estimated a RD of 3.22 (95%CI -0.31 to 6.75) febrile seizure events per  
271 100,000 mRNA-1273 vaccinations, and -0.25 (95%CI -2.75 to 2.24) febrile seizure events per  
272 100,000 BNT162b2 vaccinations (Table 3).

273 Sensitivity analysis results were consistent in direction and magnitude with the primary analysis  
274 (Figure 1). Farrington-adjusted analyses yielded an IRR of 2.43 (95% CI: 1.35 to 4.69) following  
275 mRNA-1273 and 1.26 (95%CI: 0.38 to 4.15) following BNT162b2. Analysis on the subset of the  
276 population without concomitant vaccinations yielded an IRR of 2.54 (95% CI: 1.19 to 5.42)  
277 following mRNA-1273 and 1.64 (95%CI: 0.61 to 4.42) following BNT162b2. Analyses  
278 adjusting for seasonality of seizures resulted in an IRR of 2.51 (95% CI: 1.27 to 4.96) following  
279 mRNA-1273 and 1.31 (95%CI: 0.42 to 4.01) following BNT162b2. Finally, PPV-adjusted  
280 analyses showed an IRR 2.53 (95% CI: 1.17 to 5.47) following mRNA-1273 and 1.38 (95%CI:  
281 0.48 to 4.02) following BNT162b2.

282 IRRs from analyses in individual databases are displayed in eFigure 1. IRRs following  
283 mRNA1273 were consistently elevated across databases, though only the results in the CVS  
284 Health database were significant (Optum IRR=2.19, 95% CI: 0.49 to 9.85; Carelon IRR=1.68,  
285 95% CI: 0.5 to 5.61; CVS IRR=3.59, 95% CI: 1.33 to 9.67). IRRs showed more variation  
286 between databases following BNT16b2 vaccination, with significant elevated incidence rate  
287 ratios observed only in the Optum database (Optum IRR=3.07, 95% CI: 1.04 to 9.10; Carelon  
288 IRR=0.43, 95% CI: 0.06 to 3.17; CVS IRR=0.96, 95% CI: 0.23 to 4.03). Sensitivity analysis  
289 results from individual databases were largely consistent with the primary analysis results from  
290 the databases.

## 291 **Secondary Outcomes**

292 In the secondary outcomes using a longer risk interval (0-7 days), there were 103 cases of febrile  
293 seizures and 135 cases of seizures/convulsions observed following vaccination with BNT162b2,  
294 of which 22 cases of febrile seizures and 32 cases of seizures/convulsions were observed during  
295 the risk interval. There were 78 cases of febrile seizures and 106 cases of seizures/convulsions  
296 observed following vaccination with mRNA-1273, of which 21 cases of febrile seizures and 28  
297 cases of seizures/convulsions were observed during the risk interval.

298 No statistically significant results were observed in the meta-analysis nor in individual databases  
299 for the secondary outcomes (eFigures 2-3). Additionally, no statistically significant results were  
300 observed for the secondary outcome populations in any of the analyses with adjustments.

### 301 **DISCUSSION (Word Count: 979)**

302 In our study of large cohorts aged 2-5 years in three U.S. commercial health insurance databases,  
303 our primary meta-analysis identified a statistically significant increased incidence of febrile  
304 seizures among ages 2-4 years in the 0-1 days following mRNA-1273 vaccination. No  
305 significantly increased incidence was identified following BNT162b2 vaccination among ages 2-  
306 5 years. Database specific results showed increased incidence of febrile seizure immediately  
307 following BNT162b2 vaccination in the Optum database and for the mRNA-1273 vaccine in the  
308 CVS Health database. No significant increased incidence was identified for secondary outcomes  
309 including febrile seizures in the 0-7 days following vaccination and seizures/convulsions in the  
310 0-7 day risk window.

311 Though our primary meta-analysis showed a relative risk near 2.5 for febrile seizures  
312 immediately following mRNA-1273 vaccination, we estimated the risk difference of febrile  
313 seizures following vaccination to be small. In the 0-1 day risk interval following over 190,000

314 eligible mRNA-1273 vaccinations only 10 febrile seizure cases were observed. Our analysis  
315 found a risk difference of approximately 3 additional cases of febrile seizures per 100,000  
316 mRNA-1273 vaccinations, though the range from the confidence interval for the estimate  
317 included the potential for fewer than zero febrile seizure events per 100,000 vaccinations. The  
318 uncertainty in our estimates reflected the rarity of the event. We did not find a statistically  
319 significant estimate following BNT162b2 vaccination. Furthermore, there was a lack of  
320 consistency in directionality of the incidence rate ratio and attributable risk estimates following  
321 BNT1262. This uncertainty is likely due to variation from small case counts and a small number  
322 of databases contributing to the meta-analysis.

323 Our meta-analysis results showed a significantly increased incidence following mRNA-1273 but  
324 not following BNT162b2 vaccination. The difference in formulation of the two vaccinations may  
325 yield a different immune reaction. The mRNA-1273 vaccination contains 25 µg of antigen per  
326 0.25mL dose, while the BNT162b2 vaccination contains 3 µg of antigen per 0.3mL dose.

327 Other studies from clinical trials, active surveillance systems, and passive surveillance systems  
328 found febrile seizures to be rare and did not report any increased risk for febrile seizures  
329 following COVID-19 vaccination in children under 5 years of age. Initial vaccine safety data  
330 indicate that among young children, seizures/convulsions following COVID-19 mRNA vaccines  
331 are rare: A clinical trial of 3,013 vaccine recipients in children aged 6 months to 4 years reported  
332 5 febrile convulsions cases and only one of those (in a 6-month-old participant) was considered  
333 possibly related to the BNT162b2 vaccination or may also have been caused by a concurrent  
334 viral infection.<sup>13</sup> In an analysis of the passive surveillance Vaccine Adverse Event Reporting  
335 System (VAERS) data, only 8 seizures were identified following approximately one million  
336 COVID-19 mRNA vaccinations through August 2022 in the age group 6 months to 5 years. Six

337 of the 8 seizures were afebrile on medical evaluation.<sup>14</sup> In CBER's NRS of the bivalent  
338 formulations of the mRNA vaccines authorized in December 2022 for the youngest age groups,  
339 no seizures/convulsions outcomes were identified in vaccinees aged 2-5 among 611 person-years  
340 of follow up.

341 It is important to note that febrile seizures occur at rate of up to 5% in young children.<sup>15</sup> The risk  
342 difference we found of 3 additional cases of febrile seizures per 100,000 mRNA-1273  
343 vaccinations is not large compared to some other vaccines and combinations of vaccines which  
344 may carry a small risk of at most 30 febrile seizures in 100,000 children vaccinated.

345 Our study has several strengths. First, our study included a large, geographically diverse  
346 population from three US commercial health insurance databases. Our use of a self-controlled  
347 study design inherently adjusted for time-invariant confounders such as health conditions,  
348 socioeconomic status, and demographic characteristics that may introduce bias in other study  
349 designs using between-individual comparisons. We adjusted for time-varying confounding such  
350 as seasonality in our sensitivity analyses. Our study sampled vaccinated cases from health plan  
351 and public health authority data and not from individual-level reports of vaccination status and  
352 therefore was not subject to bias due to underreporting of vaccination status. Our study used IIS  
353 data to supplement claims-based vaccination information thus increasing sample size of SCCS  
354 study for these rare outcomes. Finally, our outcome definition was shown to have a high PPV;<sup>16</sup>  
355 therefore, our study was able to minimize potential outcome misclassification bias.

356 Our study also has some limitations. First, the rarity of the event led to substantial uncertainty in  
357 estimates, and our study was not powered to identify very small increases in risks. The small  
358 number of outcomes further prevented us from performing dose-specific analyses or further  
359 subgroup analyses. We may have omitted some beneficiaries with outcomes due to delayed

360 reporting; however, we selected study end dates to ensure 85% data completeness. Furthermore,  
361 we conducted PPV adjustment using the Sentinel Initiative’s PPV estimates as medical record  
362 review for this study is still underway for our population. Sentinel Initiative’s PPV estimates  
363 may not be generalizable to our population as they were based on ICD-9 codes. Because of the  
364 low number of databases in the meta-analysis, the statistics for measuring heterogeneity between  
365 studies could be biased. Due to low observed counts and different formulation, this study focused  
366 on monovalent mRNA vaccines and did not include bivalent formulations. Finally, though we  
367 did adjust for seasonality, there may be additional bias from unmeasured time-varying covariates  
368 such as circulating respiratory viruses such as SARS-CoV-2 and influenza.

### 369 **Conclusions**

370 Our study found an approximately 2.5 times increased incidence of febrile seizures among those  
371 aged 2-4 years in the 0-1 days following monovalent mRNA-1273 vaccination. However,  
372 absolute risk was low. Based on the current body of scientific evidence, the safety profile of the  
373 monovalent mRNA vaccines remains favorable for use in young children. Safety monitoring  
374 continues as new COVID-19 vaccines become available for children. This study was conducted  
375 under the FDA Biologics Effectiveness and Safety (BEST) Initiative, which plays a major role in  
376 the larger US federal government vaccine safety monitoring efforts and further supports  
377 regulatory decision-making regarding COVID-19 vaccines.

378  
379  
380  
381  
382  
383  
384  
385

386 **Acknowledgements:** Bowen Chen, Vincent Varvaro, Xi Li of Acumen, LLC; Shiva Vojjala,  
387 Ramya Avula, Shiva Chaudhary, Shanthi P Sagare, Ramin Riahi, Brian Greenwald, Mia Si,  
388 Dianna Hayden, and Grace Stockbower of Carelon Research; Michael Goodman, Ken Revett,  
389 Ruth Weed, and Nerissa Williams of IQVIA; Lauren Peetluk, PhD, MPH, Elizabeth J. Bell, PhD,  
390 MPH, Wafa Tarazi, PhD, MHPA, Alexandra Stone, PhD, MS of Optum; and Anne Marie Kline  
391 MS, CHES, Nancy B. Shaik, BS, Ana M Martinez-Baquero, MA, Vaibhav Sharma, MS, Smita  
392 Bhatia, MCA, Yi Liu, MDA, MS, Xun Zhang, MMS, Eugenio Abente, PhD, Jonathan P  
393 Deshazo, PhD, MPH, Aparna Srikanti, MSc, Ralph Webber, BS, Charlalynn Harris , PhD, MPH,  
394 Wuan M Head, BA, Harpreet Kaur Dhillon, MCA, Carla Brannan, BA, Jack Dimpel, and James  
395 Dunlap of CVS Health for their assistance with data validation, analysis, and project  
396 coordination.

397

398

399

400

401

402



## 403 References

- 404 1. U.S. Food & Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes  
405 Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of  
406 Age. 2022; <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children>,  
407 2023.
- 409 2. Centers for Disease Control and Prevention. Stay Up to Date with COVID-19 Vaccines.  
410 2023; <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html>, 2023.
- 411 3. U.S. Food & Drug Administration. Vaccines and Related Biological Products Advisory  
412 Committee Meeting: FDA Review of Effectiveness and Safety of Moderna COVID-19  
413 Vaccine in Children 6 Months through 5 Years of Age, Emergency Use Authorization  
414 Amendment. 2022; <https://www.fda.gov/media/159254/download>.
- 415 4. U.S. Food & Drug Administration. Vaccines and Related Biological Products Advisory  
416 Committee Meeting: FDA Review of Effectiveness and Safety of Pfizer-BioNTech  
417 COVID-19 Vaccine in Children 6 Months through 4 Years of Age, Emergency Use  
418 Authorization Amendment. 2022; <https://www.fda.gov/media/159255/download>.
- 419 5. U.S. Food & Drug Administration. COVID-19 Vaccine Safety Surveillance. 2021;  
420 [https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/covid-19-](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/covid-19-vaccine-safety-surveillance)  
421 [vaccine-safety-surveillance](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/covid-19-vaccine-safety-surveillance), 2023.
- 422 6. Hu M, Shoabi A, Feng Y, et al. Safety of Monovalent BNT162b2 (Pfizer-BioNTech),  
423 mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 Vaccines in US  
424 Children Aged 6 months to 17 years. 2023:2023.2010.2013.23296903.
- 425 7. Kawai AT, Martin DB, Kulldorff M, et al. *Assessment of Febrile Seizures After Trivalent*  
426 *Influenza Vaccines During the 2010-2011 Influenza Season in the Post-Licensure Rapid*  
427 *Immunization Safety Monitoring Program*. Mini-Sentinel: U.S. Food & Drug  
428 Administration;2014.
- 429 8. U.S. Food & Drug Administration. FDA Evaluation of a Preliminary Seizure Safety  
430 Signal from Rapid Surveillance of Children Ages 2 – 4/5 yrs. following COVID-19  
431 mRNA Vaccination. 2023; [https://bestinitiative.org/wp-](https://bestinitiative.org/wp-content/uploads/2023/07/BEST_Prelim_Seizure_Safety_Signal_Ages-2-5_2023.pdf)  
432 [content/uploads/2023/07/BEST Prelim Seizure Safety Signal Ages-2-5 2023.pdf](https://bestinitiative.org/wp-content/uploads/2023/07/BEST_Prelim_Seizure_Safety_Signal_Ages-2-5_2023.pdf),  
433 2023.
- 434 9. Wilson K, Hawken S. Drug safety studies and measures of effect using the self-controlled  
435 case series design. *Pharmacoepidemiology and Drug Safety*. 2012;22(1):108-110.
- 436 10. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis.  
437 2002;21(11):1539-1558.
- 438 11. Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored, perturbed, or  
439 curtailed post-event exposures. *Biostatistics*. 2009;10(1):3-16.
- 440 12. Rubin DB, Schenker N. Multiple Imputation for Interval Estimation From Simple  
441 Random Samples With Ignorable Nonresponse. *Journal of the American Statistical*  
442 *Association*. 1986;81(394):366-374.
- 443 13. U.S. Food & Drug Administration. Vaccines and Related Biological Products Advisory  
444 Committee Meeting June 15, 2022, FDA Briefing Document: EUA amendment request  
445 for Pfizer-BioNTech COVID-19 Vaccine for use in children 6 months through 4 years of  
446 age. In:2022.

- 447 14. Hause AM, Marquez P, Zhang B, et al. *COVID-19 mRNA Vaccine Safety Among*  
448 *Children Aged 6 Months–5 Years — United States, June 18, 2022–August 21, 2022.*  
449 *Morbidity and Mortality Weekly Report (MMWR): Centers for Disease Control and*  
450 *Prevention; September 2, 2022 2022.*
- 451 15. Centers for Disease Control and Prevention. Febrile Seizures.  
452 [https://www.cdc.gov/vaccinesafety/concerns/febrile-](https://www.cdc.gov/vaccinesafety/concerns/febrile-seizures.html#:~:text=A%20CDC%20study%20of%20children,tetanus%2C%20acellular%20pertussis%20(DTaP).)  
453 [seizures.html#:~:text=A%20CDC%20study%20of%20children,tetanus%2C%20acellular](https://www.cdc.gov/vaccinesafety/concerns/febrile-seizures.html#:~:text=A%20CDC%20study%20of%20children,tetanus%2C%20acellular%20pertussis%20(DTaP).)  
454 [%20pertussis%20\(DTaP\)](https://www.cdc.gov/vaccinesafety/concerns/febrile-seizures.html#:~:text=A%20CDC%20study%20of%20children,tetanus%2C%20acellular%20pertussis%20(DTaP).). Accessed February 6, 2024.
- 455 16. Kawai AT, Martin D, Henrickson SE, et al. Validation of febrile seizures identified in the  
456 Sentinel Post-Licensure Rapid Immunization Safety Monitoring Program. *Vaccine.*  
457 2019;37(30):4172-4176.

458

459

460

461

462

463

464

465

466

467 **Figures Legend**

468 Figure 1. Incidence Rate Ratios for Primary and Sensitivity Random-Effects Meta-Analyses,  
469 Febrile Seizures (0-1 Days) Outcome illustrates incidence rate ratios and 95% confidence  
470 intervals across analyses for direct comparison.

471 Figure e1. Incidence Rate Ratios, Random Effects Meta-Analysis and Individual Database  
472 Results, Primary Outcome: Febrile Seizure (0-1 Day Risk Interval) illustrates incidence rate  
473 ratios and 95% confidence intervals across individual databases for all analyses of the primary  
474 outcome.

475 eFigure 2. Incidence Rate Ratios, Random Effects Meta-Analysis and Individual Database  
476 Results, Secondary Outcome: Febrile Seizure (0-7 Day Risk Interval) illustrates incidence rate  
477 ratios and 95% confidence intervals across individual databases for all analyses of the secondary  
478 febrile seizure outcome.

479 eFigure 3. Incidence Rate Ratios, Random Effects Meta-Analysis and Individual Database  
480 Results, Secondary Outcome: Seizure (0-7 Day Risk Interval) illustrates incidence rate ratios and  
481 95% confidence intervals across individual databases for all analyses of the secondary  
482 seizure/convulsion outcome.

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500 **Tables**

501 **Table 1. Characteristics of Vaccinated Patients and Patients With Febrile Seizures Aged 2-4 Years**  
 502 **(BNT162b2) and 2-5 Years (mRNA-1273), Combined Across Databases**

Patient Characteristic	BNT162b2								mRNA-1273							
	Eligible Vaccinees		Outcome						Eligible Vaccinees		Outcome					
			Febrile Seizure (0-1 Days)								Febrile Seizure (0-1 Days)					
			Risk & Control Intervals		In Risk Interval		In Control Interval				Risk & Control Intervals		In Risk Interval		In Control Interval	
#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	
<b>Total</b>	163,733	100.0%	88	100.0%	7	100.0%	81	100.0%	110,126	100.0%	67	100.0%	10	100.0%	57	100.0%
<b>Age</b>																
2 years	53,485	32.7%	52	59.1%	*	*	*	*	35,300	32.1%	42	62.7%	5	50.0%	37	64.9%
3 years	56,052	34.2%	19	21.6%	*	*	*	*	35,075	31.8%	17	25.4%	*	*	*	*
4 years	54,196	33.1%	17	19.3%	*	*	*	*	34,520	31.3%	*	*	*	*	*	*
5 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	5,231	4.8%	*	*	*	*	*	*
<b>Sex</b>																
Female	80,214	49.0%	32	36.4%	*	*	*	*	53,967	49.0%	26	38.8%	6	60.0%	20	35.1%
Male	83,496	51.0%	56	63.6%	*	*	*	*	56,147	51.0%	41	61.2%	*	*	*	*
Missing/Unknown	23	0.0%	0	0.0%	0	0.0%	0	0.0%	12	0.0%	*	*	*	*	*	*
<b>HHS Region</b>																
Region 1	11,642	7.1%	10	11.4%	*	*	*	*	9,562	8.7%	9	13.4%	*	*	*	*
Region 2	17,878	10.9%	12	13.6%	*	*	*	*	16,074	14.6%	7	10.4%	*	*	*	*
Region 3	19,330	11.8%	8	9.1%	0	0.0%	8	9.9%	13,824	12.6%	10	14.9%	*	*	*	*
Region 4	21,098	12.9%	11	12.5%	0	0.0%	11	13.6%	10,597	9.6%	5	7.5%	*	*	*	*
Region 5	30,668	18.7%	18	20.5%	*	*	*	*	15,023	13.6%	5	7.5%	*	*	*	*
Region 6	14,344	8.8%	*	*	*	*	*	*	7,734	7.0%	*	*	*	*	*	*
Region 7	7,500	4.6%	*	*	*	*	*	*	4,216	3.8%	*	*	*	*	*	*
Region 8	7,859	4.8%	5	5.7%	0	0.0%	5	6.2%	4,359	4.0%	*	*	*	*	*	*
Region 9	27,105	16.6%	16	18.2%	0	0.0%	16	19.8%	22,382	20.3%	19	28.4%	*	*	*	*
Region 10	6,131	3.7%	*	*	*	*	*	*	6,230	5.7%	*	*	*	*	*	*
Missing/Unknown	178	0.1%	0	0.0%	0	0.0%	0	0.0%	125	0.1%	0	0.0%	0	0.0%	0	0.0%
<b>Urban/Rural</b>																
Urban	159,169	97.2%	86	97.7%	6	85.7%	80	98.8%	107,306	97.4%	65	97.0%	10	100.0%	55	96.5%
Rural	4,376	2.7%	*	*	*	*	*	*	2,680	2.4%	*	*	*	*	*	*
Missing/Unknown	188	0.1%	*	*	*	*	*	*	140	0.1%	*	*	*	*	*	*

503 \*Cells <5 or cells that can be used to back calculate cells <5 are masked to avoid identification

504 Data cutoffs for 85% data completeness: Carelon Research – 02/04/2023, CVS Health – 03/26/2023, Optum – 05/20/2023

505

506

507 **Table 2. Incidence Rate Ratios for Primary and Sensitivity Meta-Analyses, Febrile Seizure (0-1 Days) Outcome**

Analysis	Brand	Count of Cases		Count of Days		Random Effects Meta-Analysis		Fixed Effects Meta-Analysis			Between-Study Var. ( $\tau^2$ )			Cochran's Q		I <sup>2</sup>			
		Risk	Control	Risk	Control	RR	95% CI	RR	95% CI	Est.	95% CI	Est.	P-Value	Est.	95% CI				
		Primary Analysis	BNT-162b2	7	81	296	4,318	1.41	0.48	4.11	1.85	0.94	3.62	0.43	0.00	36.07	4.07	0.13	0.51
Farrington-Adjusted	7	81		296	4,318	1.26	0.38	4.15	1.51	0.67	3.42	0.54	0.00	45.33	3.91	0.14	0.49	0.00	0.85
Non-Concomitant Vaccines	7	65		252	3,547	1.64	0.61	4.42	1.81	0.81	4.03	0.23	0.00	31.36	2.88	0.24	0.31	0.00	0.93
Seasonality Adjusted	7	81		296	4,318	1.31	0.42	4.01	1.54	0.69	3.41	0.44	0.00	39.27	3.71	0.16	0.46	0.00	0.84
PPV-Adjusted	6	74		269	3,929	1.38	0.48	4.02	1.52	0.63	3.65	0.26	0.00	34.13	2.87	0.24	0.30	0.00	0.93
Primary Analysis	mRNA-1273	10	57	234	3,319	<b>2.52</b>	<b>1.35</b>	<b>4.69</b>	<b>2.52</b>	<b>1.35</b>	<b>4.69</b>	0.00	0.00	5.43	0.95	0.62	0.00	0.00	0.78
Farrington-Adjusted		10	57	234	3,319	<b>2.43</b>	<b>1.20</b>	<b>4.90</b>	<b>2.43</b>	<b>1.20</b>	<b>4.90</b>	0.00	0.00	3.23	0.51	0.77	0.00	0.00	0.59
Non-Concomitant Vaccines		8	47	194	2,738	<b>2.54</b>	<b>1.19</b>	<b>5.42</b>	<b>2.54</b>	<b>1.19</b>	<b>5.42</b>	0.00	0.00	9.46	1.03	0.60	0.00	0.00	0.80
Seasonality Adjusted		10	57	234	3,319	<b>2.51</b>	<b>1.27</b>	<b>4.96</b>	<b>2.51</b>	<b>1.27</b>	<b>4.96</b>	0.00	0.00	4.79	0.83	0.66	0.00	0.00	0.90
PPV-Adjusted		9	52	213	3,017	<b>2.53</b>	<b>1.17</b>	<b>5.47</b>	<b>2.53</b>	<b>1.17</b>	<b>5.47</b>	0.00	0.00	5.86	0.80	0.67	0.00	0.00	0.90

508

509

510 **Table 3. Risk Difference (RD) Estimates for Primary and Sensitivity Meta-Analyses, Febrile Seizures (0-1 Days Outcome)**

Analysis	Brand	Eligible Vaccinations	Eligible Person-Years	Random-Effects Meta-Analysis						Fixed Effects Meta-Analysis					
				RD Per 100k Doses			RD Per 100k Person-Years			RD Per 100k Doses			RD Per 100k Person-Years		
				AR	95% CI		AR	95% CI		AR	95% CI		AR	95% CI	
Primary Analysis	BNT-162b2	288,754	1,580.0	-0.25	-2.75	2.24	-46.01	-501.88	409.86	-0.66	-2.26	0.94	-120.57	-413.04	171.91
Farrington-Adjusted		288,754	1,580.0	0.00	-2.55	2.55	0.25	-465.60	466.10	-0.77	-1.83	0.28	-141.55	-333.91	50.81
Non-Concomitant Vaccines		232,484	1,272.4	0.29	-2.18	2.77	53.03	-399.18	505.24	-0.21	-1.81	1.38	-38.93	-330.27	252.40
Seasonality Adjusted		289,115	1,582.0	-0.09	-2.38	2.19	-17.10	-434.33	400.12	-0.66	-1.95	0.63	-120.69	-356.99	115.61
PPV-Adjusted		289,115	1,582.0	-0.18	-2.02	1.66	-32.25	-368.72	304.22	-0.49	-1.77	0.79	-89.93	-323.52	143.65
Primary Analysis	mRNA-1273	192,540	1,053.6	3.22	-0.31	6.75	587.81	-57.35	1232.96	3.22	-0.31	6.75	587.81	-57.35	1232.96
Farrington-Adjusted		192,540	1,053.6	<b>2.49</b>	<b>0.19</b>	<b>4.80</b>	<b>455.55</b>	<b>33.94</b>	<b>877.15</b>	<b>2.49</b>	<b>0.19</b>	<b>4.80</b>	<b>455.55</b>	<b>33.94</b>	<b>877.15</b>
Non-Concomitant Vaccines		159,157	871.1	2.35	-0.66	5.36	429.54	-119.83	978.90	2.35	-0.66	5.36	429.54	-119.83	978.90
Seasonality Adjusted		193,188	1,057.1	2.58	-0.21	5.38	472.23	-37.94	982.40	2.58	-0.21	5.38	472.23	-37.94	982.40
PPV-Adjusted		193,188	1,057.1	2.33	-0.50	5.17	426.12	-92.18	944.43	2.33	-0.50	5.17	426.12	-92.18	944.43

511


512



# Meta-Analysis IRR Comparison, Primary Outcome: Febrile Seizure (0-1 Days)


BNT162b2

	Risk Cases	Control Cases
<b>Primary Analysis</b>	7	81
<b>Event Dependent Exposure Analysis</b>	7	81
<b>Non-Concomitant Vaccination Subgroup</b>	7	65
<b>Seasonality Adjusted Analysis</b>	7	81
<b>PPV Adjusted Analysis</b>	6	74



medRxiv preprint doi: <https://doi.org/10.1101/2021.05.11.21252173>; this version posted May 11, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

	Risk Cases	Control Cases
<b>Primary Analysis</b>	10	57
<b>Event Dependent Exposure Analysis</b>	10	57
<b>Non-Concomitant Vaccination Subgroup</b>	8	47
<b>Seasonality Adjusted Analysis</b>	10	57
<b>PPV Adjusted Analysis</b>	9	52



Incidence Rate Ratio

mRNA-1273